Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Horizon Pharma PLC Stock Research

HZNP

115.61USD+0.11(+0.10%)Market Closed
Watchlist

Market Summary

USD115.61+0.11
Market Closed
0.10%

HZNP Alerts

  • Big jump in Earnings (Y/Y)

HZNP Stock Price

HZNP RSI Chart

HZNP Valuation

Market Cap

26.5B

Price/Earnings (Trailing)

60.43

Price/Sales (Trailing)

7.26

EV/EBITDA

24.69

Price/Free Cashflow

27.62

HZNP Price/Sales (Trailing)

HZNP Profitability

EBT Margin

10.44%

Return on Equity

7.3%

Return on Assets

4.14%

Free Cashflow Yield

3.62%

HZNP Fundamentals

HZNP Revenue

Revenue (TTM)

3.6B

Revenue Y/Y

7.82%

Revenue Q/Q

13.57%

HZNP Earnings

Earnings (TTM)

438.0M

Earnings Y/Y

108.4%

Earnings Q/Q

132.37%

Price Action

52 Week Range

60.03115.73
(Low)(High)

Last 7 days

0.3%

Last 30 days

8.9%

Last 90 days

12.7%

Trailing 12 Months

84.6%

HZNP Financial Health

Current Ratio

4.07

Debt/Equity

0.51

Debt/Cashflow

0.49

HZNP Investor Care

Buy Backs (1Y)

0.47%

Diluted EPS (TTM)

1.87

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for HZNP

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-06
SHERMAN JEFFREY W
gifted
-
-
-2,165
evp and chief medical officer
2023-05-09
Himawan Jeff
gifted
-
-
7,873
-
2023-05-09
Himawan Jeff
gifted
-
-
-7,873
-
2023-04-28
Watkins Thomas
acquired
-
-
3,913
-
2023-04-28
Witz Pascale
acquired
-
-
3,913
-
2023-04-28
Witz Pascale
sold (taxes)
-208,870
111
-1,879
-
2023-04-28
Shannon James Samuel
acquired
-
-
3,913
-
2023-04-28
Daniel William F
sold (taxes)
-208,870
111
-1,879
-
2023-04-28
Mahony Susan
sold (taxes)
-208,870
111
-1,879
-
2023-04-28
Himawan Jeff
acquired
-
-
3,913
-

1–10 of 50

Which funds bought or sold HZNP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
added
3,462
14,148,400
14,679,400
0.12%
2023-09-20
BARCLAYS PLC
reduced
-36.71
-68,159,000
100,710,000
0.06%
2023-09-12
Farther Finance Advisors, LLC
reduced
-0.1
-6,575
105,730
0.02%
2023-09-11
BLUEFIN CAPITAL MANAGEMENT, LLC
new
-
5,921,790
5,921,790
1.13%
2023-08-23
Stonebridge Capital Advisors LLC
unchanged
-
-314
5,143
-%
2023-08-23
CTC Alternative Strategies, Ltd.
new
-
638,699
638,699
0.80%
2023-08-22
COMERICA BANK
new
-
90,000
90,000
0.01%
2023-08-22
Asset Dedication, LLC
unchanged
-
-
1,000
-%
2023-08-21
Affinity Asset Advisors, LLC
sold off
-100
-2,182,800
-
-%
2023-08-21
VisionPoint Advisory Group, LLC
new
-
41,140
41,140
0.02%

1–10 of 43

Latest Funds Activity

Are funds buying HZNP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HZNP
No. of Funds

Schedule 13G FIlings of Horizon Pharma

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 09, 2023
vanguard group inc
9.37%
21,236,103
SC 13G/A
Feb 09, 2023
fmr llc
-
0
SC 13G/A
Feb 07, 2023
blackrock inc.
6.5%
14,794,254
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 03, 2022
blackrock inc.
5.7%
13,008,024
SC 13G/A
Feb 11, 2021
renaissance technologies llc
3.08%
6,798,963
SC 13G/A
Feb 10, 2021
vanguard group inc
9.03%
19,920,258
SC 13G/A
Feb 08, 2021
fmr llc
-
0
SC 13G
Jan 29, 2021
blackrock inc.
6.4%
14,206,978
SC 13G/A
Feb 12, 2020
vanguard group inc
9.12%
17,089,414
SC 13G/A

Recent SEC filings of Horizon Pharma

View All Filings
Date Filed Form Type Document
Sep 12, 2023
8-K
Current Report
Sep 07, 2023
4
Insider Trading
Sep 05, 2023
8-K
Current Report
Sep 01, 2023
8-K
Current Report
Aug 08, 2023
10-Q
Quarterly Report
Aug 08, 2023
8-K
Current Report
Jul 28, 2023
4
Insider Trading
Jul 28, 2023
4
Insider Trading
Jul 28, 2023
4
Insider Trading
Jul 28, 2023
4
Insider Trading

Peers (Alternatives to Horizon Pharma)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
495.3B
29.5B
-0.51% 77.59%
76.23
16.78
1.53% 14.16%
417.0B
97.8B
-1.74% -2.10%
31.95
4.27
2.29% -28.92%
272.8B
58.3B
-4.46% 23.17%
17.88
4.63
2.00% -81.24%
184.6B
77.9B
-10.83% -26.03%
8.6
2.37
-23.04% -26.74%
150.1B
45.2B
-4.32% -16.75%
23.72
3.25
-4.15% 20.34%
MID-CAP
6.5B
-
1.87% 616.21%
-74.09
4.1K
-86.94% 71.24%
4.4B
4.6B
-14.86% -16.47%
-64.45
0.94
6.60% 42.04%
SMALL-CAP
1.6B
627.1M
-7.75% -14.29%
-1.08
2.51
-0.20% -204.67%
1.5B
634.0M
-12.24% -14.48%
35.26
2.41
0.62% -24.59%
841.4M
244.3M
-2.86% 8.68%
4.27
3.44
-39.50% -4.99%
792.7M
109.5M
17.51% -27.27%
-5.52
7.24
-2.66% -32.13%
470.6M
31.2M
-8.53% -51.99%
-4.47
15.1
407.54% -26.47%
462.3M
453.3M
100.98% -69.12%
-0.38
1.02
-16.04% 55.90%
252.8M
54.6M
-17.14% -44.23%
-2.79
4.63
9.39% -179.16%
-
2.2B
- -
-
-
-22.39% 63.59%

Horizon Pharma News

The Motley Fool
Why Horizon Therapeutics Stock Is Crashing Today.
The Motley Fool,
4 months ago
The Pharma Letter
Investor's Business Daily

Returns for HZNP

Cumulative Returns on HZNP

41.9%


10-Year Cumulative Returns

29.0%


7-Year Cumulative Returns

43.8%


5-Year Cumulative Returns

13.9%


3-Year Cumulative Returns

Risks for HZNP

What is the probability of a big loss on HZNP?

50.4%


Probability that Horizon Pharma stock will be more than 20% underwater in next one year

37.3%


Probability that Horizon Pharma stock will be more than 30% underwater in next one year.

14.2%


Probability that Horizon Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does HZNP drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Horizon Pharma was unfortunately bought at previous high price.

Drawdowns

Financials for Horizon Pharma

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue1.9%3,6443,5763,6293,7013,8133,7693,2262,9572,5572,1872,2001,8191,5181,3761,3001,2921,2821,2641,2081,1261,073
Gross Profit3.0%2,7412,6622,7092,7812,8752,8602,4322,2421,9421,6511,6681,3531,1141,004938926915895816690602
Operating Expenses1.1%2,2282,2032,0912,1042,0271,9631,8891,6921,4941,3051,1781,049989892811772747741778802802
  S&GA Expenses2.2%1,6581,6221,5411,5671,5301,4871,4461,3241,1901,057973882828773697686676685692685678
  R&D Expenses10.0%51646943842239743434527821815912916716110910394.0091.0087.0083.0094.0091.00
EBITDA-100.0%-8851,0241,0641,223917736559465492621414180149130------
EBITDA Margin-100.0%-0.25*0.28*0.29*0.32*0.24*0.23*0.19*0.18*0.22*0.28*0.23*0.12*0.11*0.10*------
Interest Expenses14.2%13912210692.0084.0083.0074.0065.0054.0044.0052.0055.0059.0089.0078.00117106113112107111
Earnings Before Taxes18.9%444373527584756807463481376263402209-5.11-18.06-20.22-4.5140.0030.00-83.13-234-323
EBT Margin-100.0%-0.10*0.15*0.16*0.20*0.21*0.14*0.16*0.15*0.12*0.18*0.11*0.00*-0.01*-0.02*------
Net Income17.8%43837252157476586253455251828039079251759257382.0097.0077.00-38.38-178-275
Net Income Margin-100.0%-0.10*0.14*0.16*0.20*0.23*0.17*0.19*0.20*0.13*0.18*0.44*0.34*0.43*0.44*------
Free Cashflow-100.0%-1,0541,1941,3141,3461,182959810522545386197185173408------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets3.4%9,2998,9939,1159,0288,8538,7408,6788,6098,2077,8476,0735,7674,5384,3154,4363,7213,7083,9363,9424,0193,990
  Current Assets8.9%3,9223,6033,6533,4123,2032,9482,8002,4142,1751,8313,0702,7321,4891,4141,6861,4791,4021,5601,5461,3391,235
    Cash Equivalents6.6%2,4652,3122,3532,1311,8931,6431,5801,0698128122,0801,7257187551,0768848661,033959807710
  Inventory3.5%17016417019020422715223725923875.0077.0066.0068.0054.0059.0051.0052.0051.0053.0050.00
  Net PPE1.8%36235634131830229529228622020218915613914230.0026.0025.0022.0020.0017.0018.00
  Goodwill0%1,0111,0111,0111,0111,0111,0671,0671,0691,069663414414414414414414414414414426426
  Current Liabilities3.7%918885949861791825887854853774876784985592723636637895709692726
    LT Debt, Current------------------250---
Shareholder's Equity4.2%5,3115,0965,0725,0344,9464,8184,6724,4504,0743,8554,0253,7972,3622,1882,1851,5561,5211,5041,1901,051987
  Retained Earnings19.7%772645590606584523319145-181-339-215-406-699-619-605-1,198-1,216-1,211-1,178-1,414-1,440
  Additional Paid-In Capital1.6%4,5224,4494,4744,4254,3814,3154,3734,3114,2604,2004,2464,2093,0682,8142,7982,7612,7442,7222,3752,3382,307
Shares Outstanding0.2%229229227229230229227226225224221212193190188186185173169167165
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations-7.8%1,0411,1281,2581,3701,4151,2551,035907604615556337316308426344341312195229213
  Share Based Compensation7.8%20819318218619620521920317915114713812612091.0095.00105115115121126
Cashflow From Investing-5.8%-142-135-134-121-231-305-2,994-3,022-2,902-2,975-464-411-393-234-17.8626.0040.0038.0028.00-1.87-13.54
Cashflow From Financing-2.6%-334-326-347-177-91.16-1091,4701,4652,3922,413905913-70.57-350-290-293-2279.00-16.60-45.53-46.09
  Buy Backs---250454-----------------

HZNP Income Statement

2023-06-30
Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) - USD ($)
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]    
Net sales$ 944,959,000$ 876,411,000$ 1,777,018,000$ 1,761,656,000
Cost of goods sold219,958,000230,216,000428,521,000445,278,000
Gross profit725,001,000646,195,0001,348,497,0001,316,378,000
OPERATING EXPENSES:    
Research and development150,035,000103,246,000284,183,000206,378,000
Selling, general and administrative434,125,000398,221,000887,479,000770,955,000
Impairment of goodwill056,171,000056,171,000
Gain on sale of asset(2,000,000) (2,000,000) 
Total operating expenses582,160,000557,638,0001,169,662,0001,033,504,000
Operating income142,841,00088,557,000178,835,000282,874,000
OTHER EXPENSE, NET:    
Interest expense, net(12,098,000)(21,409,000)(27,638,000)(42,665,000)
Foreign exchange gain326,00028,000417,000448,000
Other income (expense), net4,183,000(2,389,000)2,840,000(3,131,000)
Total other expense, net(7,589,000)(23,770,000)(24,381,000)(45,348,000)
Income before expense (benefit) for income taxes135,252,00064,787,000154,454,000237,526,000
Expense (benefit) for income taxes8,181,0003,813,000(27,301,000)(27,709,000)
Net income$ 127,071,000$ 60,974,000$ 181,755,000$ 265,235,000
Net income per ordinary share—basic$ 0.56$ 0.27$ 0.80$ 1.16
Weighted average ordinary shares outstanding—basic228,743,143230,020,004228,571,356229,559,715
Net income per ordinary share—diluted$ 0.54$ 0.26$ 0.78$ 1.12
Weighted average ordinary shares outstanding—diluted233,935,591236,166,384233,938,149236,077,147
OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX    
Foreign currency translation adjustments$ 1,409,000$ (1,433,000)$ 794,000$ (1,893,000)
Pension and other post-employment benefit plan remeasurements179,000(547,000)2,003,000(222,000)
Interest rate swap contracts designated as cash flow hedges13,339,0002,011,0006,287,0002,011,000
Other comprehensive income (loss)14,927,00031,0009,084,000(104,000)
Comprehensive income$ 141,998,000$ 61,005,000$ 190,839,000$ 265,131,000

HZNP Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:  
Cash and cash equivalents$ 2,464,623$ 2,352,833
Restricted cash4,7914,755
Accounts receivable, net717,417676,347
Inventories, net170,325169,559
Prepaid expenses and other current assets564,808449,349
Total current assets3,921,9643,652,843
Property, plant and equipment, net362,326340,509
Developed technology and other intangible assets, net2,486,5652,664,777
In-process research and development810,000810,000
Goodwill1,010,5381,010,538
Deferred tax assets, net444,306431,814
Other long-term assets263,042204,135
Total assets9,298,7419,114,616
CURRENT LIABILITIES:  
Accounts payable85,543155,800
Accrued expenses and other current liabilities496,669457,557
Accrued trade discounts and rebates319,469319,780
Long-term debt-current portion16,00016,000
Total current liabilities917,681949,137
LONG-TERM LIABILITIES:  
Long-term debt, net2,541,4582,546,837
Deferred tax liabilities, net264,815342,017
Other long-term liabilities263,828204,451
Total long-term liabilities3,070,1013,093,305
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:  
Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 229,323,393 and 227,625,913 shares issued at June 30, 2023 and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares outstanding at June 30, 2023 and December 31, 2022, respectively2323
Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022(4,585)(4,585)
Additional paid-in capital4,522,1454,474,199
Accumulated other comprehensive income21,61212,528
Retained earnings771,764590,009
Total shareholders’ equity5,310,9595,072,174
Total liabilities and shareholders' equity$ 9,298,741$ 9,114,616
Timothy P. Walbert
1890
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.